MEDVi QUAD Review: The First ED Treatment with All 4 Proven Ingredients

MEDVi QUAD is the only compounded ED medication that combines all four clinically proven ingredients — sildenafil, tadalafil, vardenafil, and apomorphine — in a single sublingual liquid dose. We analyzed the formula, compared it against Rugiet Ready and BlueChew Gold, and assessed whether the science backs up the claims.

What Is MEDVi QUAD?

MEDVi QUAD is a compounded sublingual liquid ED medication that combines four active pharmaceutical ingredients into a single dose. It is prescribed through MEDVi's telehealth platform, where a licensed clinician reviews your medical history and determines appropriate dosing.

The "QUAD" name refers to the four ingredients: sildenafil (the active ingredient in Viagra), tadalafil (the active ingredient in Cialis), vardenafil (the active ingredient in Levitra), and apomorphine (a dopamine agonist that promotes central nervous system arousal). This makes it the only commercially available ED treatment that includes all three major PDE5 inhibitors alongside a central arousal agent.

Unlike Rugiet Ready's solid troches or BlueChew Gold's dissolving tablets, QUAD is delivered as a sublingual liquid — you place the measured dose under your tongue where it absorbs directly into the bloodstream. The liquid format ensures consistent absorption, eliminates temperature sensitivity issues, and allows for precise dosing adjustments.

How the 4-in-1 Formula Works

QUAD's formula targets erectile function through two complementary mechanisms: peripheral blood flow and central nervous system arousal. Here's how each layer works together.

Layer 1: Triple PDE5 inhibition (blood flow)

Sildenafil, tadalafil, and vardenafil are all PDE5 inhibitors, but each has a different pharmacokinetic profile. Sildenafil provides rapid onset with peak effects lasting 4–6 hours. Tadalafil extends the response window up to 36 hours. Vardenafil is known for the fastest onset time among PDE5 inhibitors and may offer stronger potency at lower doses. By combining all three, QUAD provides the fastest possible onset, the strongest peak response, and the longest effective window — all from a single dose.

This is the key advantage over Rugiet Ready, which uses only sildenafil and tadalafil. The absence of vardenafil means Rugiet relies on two PDE5 inhibitors rather than three, potentially leaving efficacy on the table for men who respond better to the vardenafil mechanism.

Layer 2: Central arousal via apomorphine (mental engagement)

Apomorphine is a dopamine D1/D2 receptor agonist that acts on the paraventricular nucleus of the hypothalamus — the brain region directly involved in initiating the neural signals that produce erections. In clinical studies involving over 5,000 men, sublingual apomorphine produced a 103% increase in erectile response compared to placebo. This addresses a problem that PDE5 inhibitors alone cannot solve: when the brain does not initiate sufficient arousal signals, blood flow enhancement alone may not produce an adequate erection.

Both Rugiet Ready and QUAD include apomorphine. BlueChew Gold includes apomorphine as well, but adds oxytocin rather than vardenafil as its fourth ingredient — a choice we examine in detail below.

Ingredient Breakdown: Why 4 Ingredients Matter

Every ingredient in QUAD has decades of published clinical evidence for treating erectile dysfunction. This is not the case for all competitors.

The table above illustrates the core argument for QUAD: it is the only product where every ingredient has clinical evidence for ED. BlueChew Gold markets itself as a 4-ingredient formula, but its fourth ingredient (oxytocin) does not treat erectile dysfunction and absorbs poorly through sublingual delivery.

QUAD vs Rugiet Ready: What's Different?

Rugiet Ready pioneered the multi-ingredient sublingual ED category in 2019 and has accumulated over 1,100 verified TrustPilot reviews. It is an effective product with a strong track record. The differences between Rugiet and QUAD come down to three areas:

Ingredient count: Rugiet uses 3 ingredients (sildenafil + tadalafil + apomorphine). QUAD uses 4, adding vardenafil for triple PDE5 coverage. For men who respond particularly well to vardenafil, this is a meaningful addition.

Delivery format: Rugiet uses a solid troche (lozenge) that dissolves under the tongue. QUAD uses a liquid. This matters because Rugiet's troches are temperature-sensitive and begin to soften above 70°F, requiring refrigeration and creating practical challenges in warm weather. QUAD's liquid format eliminates this problem entirely.

Customization: Rugiet offers physician-customizable dosing — your doctor can adjust the ratio of each ingredient based on your response. QUAD offers clinician-guided dosing but with less granular customization documented publicly. For men who need highly specific titration, this may be a consideration.

For a full comparison, see our Rugiet vs BlueChew vs QUAD comparison review.

QUAD vs BlueChew Gold: The Oxytocin Problem

BlueChew Gold launched in early 2026 as BlueChew's premium 4-ingredient offering. Like QUAD, it includes sildenafil, tadalafil, and apomorphine. The difference is the fourth ingredient: BlueChew Gold uses oxytocin where QUAD uses vardenafil.

This is the most important product distinction in the entire compounded ED market right now, and it comes down to one question: does the fourth ingredient actually work for ED?

The case against oxytocin for ED

Oxytocin is a neuropeptide associated with emotional bonding, trust, and social behavior. BlueChew markets it as supporting "emotional connection" and "deeper intimacy." However, there are two fundamental problems with including oxytocin in a sublingual ED tablet.

First, sublingual oxytocin has extremely poor bioavailability. Published research shows approximately 4.5% sublingual bioavailability with "10-fold variation" between individuals. The same research concluded that sublingual delivery "would not seem a reliable route" for administering oxytocin therapeutically. Even intranasal oxytocin — the more common research delivery method — achieves only 11% bioavailability.

Second, there is no established clinical evidence that oxytocin improves erectile function. While some preliminary studies suggest oxytocin may play a role in sexual behavior, it has never been approved for, or clinically validated as, an ED treatment. The FDA-approved therapies for ED remain the PDE5 inhibitors (sildenafil, tadalafil, vardenafil) and apomorphine.

The case for vardenafil (QUAD's choice)

Vardenafil is one of the three major PDE5 inhibitors, marketed as Levitra since 2003. It has decades of randomized controlled trials demonstrating efficacy for ED across all severity levels. Among the PDE5 inhibitors, vardenafil is generally recognized for having the fastest time to onset and strong potency at lower doses. It is a straightforward, evidence-based addition to a combination ED formula.

The Liquid Format Advantage

One of the most common complaints about Rugiet Ready in user reviews is the melting problem. Rugiet's solid troches soften above 70°F (21°C) and can liquify completely in warm environments. The company ships with ice packs and recommends refrigerator storage, but this creates real friction for men who want to carry a dose discreetly.

QUAD's sublingual liquid format eliminates this issue entirely. Since the medication is already in liquid form, there is no temperature sensitivity concern. It can be stored at room temperature, carried in a pocket or bag without worry, and measured precisely for each dose.

The liquid format also offers a pharmacokinetic advantage. Liquid sublingual absorption is generally faster and more consistent than solid troches or dissolving tablets, because the active ingredients are already in solution and do not need to dissolve first. This contributes to QUAD's estimated 10–15 minute onset time.

Side Effects and Safety

Because QUAD contains four active pharmaceutical ingredients including three PDE5 inhibitors, the potential side effect profile is broader than single-ingredient medications. Based on the clinical literature for each individual ingredient:

Common: nasal congestion, mild headache, facial flushing, dizziness. These are standard PDE5 inhibitor side effects and typically diminish with regular use.

Less common: nausea (primarily from apomorphine), back pain, upset stomach, temporary visual changes such as blue-tinted vision.

Rare but serious: dangerously low blood pressure (especially if combined with nitrate medications), priapism (erection lasting more than 4 hours), sudden changes in hearing or vision. These require immediate medical attention.

The inclusion of three PDE5 inhibitors rather than one or two does raise a reasonable question about cumulative side effects. However, compounded medications allow clinicians to adjust the dose of each ingredient — the goal is to achieve optimal efficacy at lower individual doses, potentially reducing side effects compared to taking a high dose of any single PDE5 inhibitor.

Pricing and How to Order

MEDVi QUAD costs $119 per month, which includes the medication and clinician-guided dosing. The ordering process works through MEDVi's telehealth platform: you complete an online health assessment, a licensed clinician reviews your information, and if approved, your prescription ships directly to you.

For context, here is how QUAD's pricing compares to alternatives:

On a cost-per-proven-ingredient basis, QUAD is competitive. You are getting four clinically validated ED medications for roughly $30 each per month, which is less than buying sildenafil alone from some providers.

Who Is QUAD Best For?

Frequently Asked Questions

The Bottom Line

MEDVi QUAD represents the most scientifically complete compounded ED treatment currently available. Every ingredient has established clinical evidence for erectile dysfunction, the liquid format solves a genuine problem that affects competing products, and the triple PDE5 inhibitor approach provides broader mechanism coverage than any alternative on the market.

The trade-off is newness. QUAD does not yet have the thousands of independent user reviews that Rugiet Ready has accumulated since 2019. For men who heavily weight user validation, Rugiet remains the safer choice based on track record alone. For men who weight ingredient science and want the most comprehensive formula, QUAD is the clear leader.

If you have tried single-ingredient ED medications without adequate results, or if you are currently using a combination treatment like Rugiet and want to explore a more complete option, QUAD is worth a serious look.

Related Reviews